Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways

Current Cancer Drug Targets

Volumn 14, Issue 7, 2014, Pages 671-683

  Xue, Nina1 ^a   Jin, Jing ^a   Liu, Di ^a   Yan, Rui ^a   Zhang, Sen ^a   Yu, Xiaoming ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Chaperone complexes; Client protein; HSP90; p23; Pancreatic cancer; Y306zh

Indexed keywords

HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; Y306ZH; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; NEW DRUG; PYRIDONE DERIVATIVE; TUMOR PROTEIN; Y306ZH COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG DOSE COMPARISON; FLUORESCENCE POLARIZATION IMMUNOASSAY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CELL CYCLE G2 PHASE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; G2 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; RANDOM ALLOCATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911492198     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140908101523     Document Type: Article

References (46)

1. Hariharan, D.; Saied, A.; Kocher, H. M. Analysis of mortality rates for pancreatic cancer across the world. HPB, 2008, 10 (1), 58-62.
2. Koorstra, J. B.; Hustinx, S. R.; Offerhaus, G. J.; Maitra, A. Pancreatic carcinogenesis. Pancreatol., 2008, 8 (2), 110-125.
3. Van Cutsem, E.; Verslype, C.; Grusenmeyer, P. A. Lessons learned in the management of advanced pancreatic cancer. J. Clin. Oncol., 2007, 25 (15), 1949-1952.
4. Maloney, A.; Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther., 2002, 2 (1), 3-24.
5. Seufferlein, T. Novel protein kinases in pancreatic cell growth and cancer. Int. J. Gastrointest. Cancer, 2002, 31 (1-3), 15-21.
6. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2 (7), 489-501.
7. Chen, S.; Shimoda, M.; Chen, J.; Matsumoto, S.; Grayburn, P. A. Transient overexpression of cyclin D2/CDK4/GLP1 genes induces proliferation and differentiation of adult pancreatic progenitors and mediates islet regeneration. Cell Cycle, 2012, 11 (4), 695-705.
8. Ogata, M.; Naito, Z.; Tanaka, S.; Moriyama, Y.; Asano, G., Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J. Nippon Med. Sch., 2000, 67 (3), 177-185.
9. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425 (6956), 407-410.
10. Obermann, W. M.; Sondermann, H.; Russo, A. A.; Pavletich, N. P.; Hartl, F. U. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol, 1998, 143 (4), 901-910.
11. Richter, K.; Buchner, J. Hsp90: chaperoning signal transduction. J. Cell. Physiol, 2001, 188 (3), 281-290.
12. Pratt, W. B.; Galigniana, M. D.; Harrell, J. M.; DeFranco, D. B. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell. Signal., 2004, 16 (8), 857-872.
13. Siligardi, G.; Hu, B.; Panaretou, B.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem., 2004, 279 (50), 51989-51998.
14. Ali, M. M.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature, 2006, 440 (7087), 1013-1017.
15. Neckers, L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem., 2003, 10 (9), 733-739.
16. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 2003, 94 (1), 15-21.
17. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem., 2008, 51 (2), 196-218.
18. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res., 2008, 68 (8), 2850-2860.
19. Sessa, C.; Shapiro, G. I.; Bhalla, K. N.; Britten, C.; Jacks, K. S.; Mita, M.; Papadimitrakopoulou, V.; Pluard, T.; Samuel, T. A.; Akimov, M.; Quadt, C.; Fernandez-Ibarra, C.; Lu, H.; Bailey, S.; Chica, S.; Banerji, U. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin. Cancer Res., 2013, 19 (13), 3671-3680.
20. Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; Drysdale, M. J. A fluorescence polarization assay for inhibitors of Hsp90. Anal. Biochem., 2006, 350 (2), 202-213.
21. Lu, C.; Liu, D.; Jin, J.; Deokar, H.; Zhang, Y.; Buolamwini, J. K.; Yu, X.; Yan, C.; Chen, X. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Bioch. Pharmacol., 2013, 85 (9), 1246-1256.
22. Grenert, J. P.; Sullivan, W. P.; Fadden, P.; Haystead, T. A.; Clark, J.; Mimnaugh, E.; Krutzsch, H.; Ochel, H. J.; Schulte, T. W.; Sausville, E.; Neckers, L. M.; Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem., 1997, 272 (38), 23 843-23850.
23. Misso, G.; Giuberti, G.; Lombardi, A.; Grimaldi, A.; Ricciardiello, F.; Giordano, A.; Tagliaferri, P.; Abbruzzese, A.; Caraglia, M. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J. Cell. Physiol., 2013, 228, (1), 130-141.
24. Chen, W. Y.; Chang, F. R.; Huang, Z. Y.; Chen, J. H.; Wu, Y. C.; Wu, C. C. Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins. J. Biol. Chem., 2008, 283 (25), 17184-17193.
25. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen., 2004, 9 (5), 375-381.
26. Ueda, S.; Ogata, S.; Tsuda, H.; Kawarabayashi, N.; Kimura, M.; Sugiura, Y.; Tamai, S.; Matsubara, O.; Hatsuse, K.; Mochizuki, H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas, 2004, 29 (1), e1-8.
27. Ballinger, C. A.; Connell, P.; Wu, Y.; Hu, Z.; Thompson, L. J.; Yin, L. Y.; Patterson, C. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol., 1999, 19 (6), 4535-4545.
28. McClellan, A. J.; Frydman, J. Molecular chaperones and the art of recognizing a lost cause. Nat. Cell Biol., 2001, 3 (2), E51-53.
29. Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med., 2004, 10 (6), 283-290.
30. Lang, S. A.; Moser, C.; Gaumann, A.; Klein, D.; Glockzin, G.; Popp, F. C.; Dahlke, M. H.; Piso, P.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res., 2007, 13 (21), 6459-6468.
31. Moser, C.; Lang, S. A.; Hackl, C.; Wagner, C.; Scheiffert, E.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res., 2012, 32 (7), 2551-2561.
32. Kim, Y. S.; Alarcon, S. V.; Lee, S.; Lee, M. J.; Giaccone, G.; Neckers, L.; Trepel, J. B. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem., 2009, 9 (15), 1479-1492.
33. Rajan, A.; Kelly, R. J.; Trepel, J. B.; Kim, Y. S.; Alarcon, S. V.; Kummar, S.; Gutierrez, M.; Crandon, S.; Zein, W. M.; Jain, L.; Mannargudi, B.; Figg, W. D.; Houk, B. E.; Shnaidman, M.; Brega, N.; Giaccone, G. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin. cancer Res., 2011, 17 (21), 6831-6839.
34. Bao, R.; Lai, C. J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; DellaRocca, S.; Xu, G. X.; Tao, X.; Zhai, H. X.; Cai, X.; Qian, C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin. Cancer Res., 2009, 15 (12), 4046-4057.
35. Lee, K. H.; Lee, J. H.; Han, S. W.; Im, S. A.; Kim, T. Y.; Oh, D. Y.; Bang, Y. J. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci., 2011, 102 (7), 1388-1395.
36. Powers, M. V.; Workman, P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer, 2006, 13 Suppl 1, S125-135.
37. Roe, S. M.; Ali, M. M.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell, 2004, 116 (1), 87-98.
38. Sullivan, W. P.; Owen, B. A.; Toft, D. O. The influence of ATP and p23 on the conformation of hsp90. J. Biol. Chem., 2002, 277 (48), 45942-45948.
39. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C. G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther., 2008, 7 (1), 162-170.
40. Lopez, T.; Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2002, 1 (4), 339-353.
41. Buck, E.; Eyzaguirre, A.; Rosenfeld-Franklin, M.; Thomson, S.; Mulvihill, M.; Barr, S.; Brown, E.; O'Connor, M.; Yao, Y.; Pachter, J.; Miglarese, M.; Epstein, D.; Iwata, K. K.; Haley, J. D.; Gibson, N. W.; Ji, Q. S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res., 2008, 68 (20), 8322-8332.
42. Cortot, A. B.; Repellin, C. E.; Shimamura, T.; Capelletti, M.; Zejnullahu, K.; Ercan, D.; Christensen, J. G.; Wong, K. K.; Gray, N. S.; Janne, P. A. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res., 2013, 73 (2), 834-843.
43. Shen, S.; Zhang, P.; Lovchik, M. A.; Li, Y.; Tang, L.; Chen, Z.; Zeng, R.; Ma, D.; Yuan, J.; Yu, Q. Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J. Cell. Biol., 2009, 185 (4), 629-639.
44. Xu, W.; Marcu, M.; Yuan, X.; Mimnaugh, E.; Patterson, C.; Neckers, L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA., 2002, 99 (20), 12847-12852.
45. Luo, W.; Zhong, J.; Chang, R.; Hu, H.; Pandey, A.; Semenza, F. L. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha. J. Biol Chem., 2010, 285 (6), 3651-3663.
46. Connell, P.; Ballinger, C. A.; Jiang, J.; Wu, Y.; Thompson, L. J.; Hohfeld, J.; Patterson, C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol., 2001, 3 (1), 93-96.